175 related articles for article (PubMed ID: 33665180)
21. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
Zhang Z; Zhang J; Xia N; Zhao Q
Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
[TBL] [Abstract][Full Text] [Related]
22. Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal.
Bencina G; Chami N; Hughes R; Weston G; Baxter C; Salomonsson S
Expert Rev Pharmacoecon Outcomes Res; 2023 Apr; 23(4):391-398. PubMed ID: 36857504
[TBL] [Abstract][Full Text] [Related]
23. Spotlight on the 9-valent HPV vaccine.
Lopalco PL
Drug Des Devel Ther; 2017; 11():35-44. PubMed ID: 28053505
[TBL] [Abstract][Full Text] [Related]
24. The burden of HPV associated cancers in two regions in Nigeria 2012-2014.
Jedy-Agba EE; Dareng EO; Adebamowo SN; Odutola M; Oga EA; Igbinoba F; Otu T; Ezeome E; Bray F; Hassan R; Adebamowo CA
Cancer Epidemiol; 2016 Dec; 45():91-97. PubMed ID: 27780076
[TBL] [Abstract][Full Text] [Related]
25. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
26. Estimating the Economic Burden of Premature Mortality Caused by Cancer in Iran: 2006-2010.
Karami-Matin B; Najafi F; Rezaei S; Khosravi A; Soofi M
Asian Pac J Cancer Prev; 2016; 17(4):2131-6. PubMed ID: 27221907
[TBL] [Abstract][Full Text] [Related]
27. Worldwide burden of cancer attributable to HPV by site, country and HPV type.
de Martel C; Plummer M; Vignat J; Franceschi S
Int J Cancer; 2017 Aug; 141(4):664-670. PubMed ID: 28369882
[TBL] [Abstract][Full Text] [Related]
28. Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study.
Rahman S; Pierce Campbell CM; Rollison DE; Wang W; Waterboer T; Michel A; Pawlita M; Villa LL; Lazcano Ponce E; Borenstein AR; Giuliano AR
PLoS One; 2016; 11(11):e0167173. PubMed ID: 27902759
[TBL] [Abstract][Full Text] [Related]
29. Global burden and economic impact of vaccine-preventable cancer mortality.
Bencina G; Oliver E; Meiwald A; Hughes R; Morais E; Weston G; Sundström K
J Med Econ; 2024 Apr; 27(sup2):9-19. PubMed ID: 38721643
[TBL] [Abstract][Full Text] [Related]
30. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
31. Estimating Economic Burden of Cancer Deaths Attributable to Smoking in Iran.
Rezaei S; Akbari Sari A; Arab M; Majdzadeh R; Mohammadpoorasl A
J Res Health Sci; 2015; 15(4):228-33. PubMed ID: 26728908
[TBL] [Abstract][Full Text] [Related]
32. Years of Potential Life Lost Because of Breast and Cervical Cancers in Guatemala.
Kihn-Alarcón AJ; Alvarado-Muñoz JF; Orozco-Fuentes LI; Calgua-Guerra E; Fuentes-de Falla V; Velarde A
JCO Glob Oncol; 2020 May; 6():761-765. PubMed ID: 32484750
[TBL] [Abstract][Full Text] [Related]
33. Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States.
Stahre M; Roeber J; Kanny D; Brewer RD; Zhang X
Prev Chronic Dis; 2014 Jun; 11():E109. PubMed ID: 24967831
[TBL] [Abstract][Full Text] [Related]
34. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006.
Ekwueme DU; Guy GP; Li C; Rim SH; Parelkar P; Chen SC
J Am Acad Dermatol; 2011 Nov; 65(5 Suppl 1):S133-43. PubMed ID: 22018062
[TBL] [Abstract][Full Text] [Related]
35. Cigarette smoking-attributable mortality and years of potential life lost--United States, 1990.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1993 Aug; 42(33):645-9. PubMed ID: 8350857
[TBL] [Abstract][Full Text] [Related]
36. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.
Petry KU; Bollaerts K; Bonanni P; Stanley M; Drury R; Joura E; Kjaer SK; Meijer CJLM; Riethmuller D; Soubeyrand B; Van Damme P; Bosch X
Hum Vaccin Immunother; 2018 Jul; 14(7):1800-1806. PubMed ID: 29553886
[TBL] [Abstract][Full Text] [Related]
37. Health and economic impact of breast cancer mortality in young women, 1970-2008.
Ekwueme DU; Guy GP; Rim SH; White A; Hall IJ; Fairley TL; Dean HD
Am J Prev Med; 2014 Jan; 46(1):71-9. PubMed ID: 24355674
[TBL] [Abstract][Full Text] [Related]
38. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature.
Guy GP; Ekwueme DU
Pharmacoeconomics; 2011 Oct; 29(10):863-74. PubMed ID: 21846158
[TBL] [Abstract][Full Text] [Related]
39. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
[TBL] [Abstract][Full Text] [Related]
40. Years of potential life lost caused by prostate cancer deaths in the United States-Projection from 2004 through 2050.
Li C; Ekwueme DU
Cancer Epidemiol; 2010 Aug; 34(4):368-72. PubMed ID: 20510666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
